• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Can We Treat Depression by Targeting Inflammation?

Can We Treat Depression by Targeting Inflammation?

September 13, 2021
Christina Guest, MD.
From The Carlat Hospital Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Christina Guest, MD. Dr. Guest has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
REVIEW OF: Zazula R et al, Aust N Z J Psychiatry 2021;55(8):784–798

Recent data suggest inflammation may play a role in depression, prompting research into the efficacy of minocycline—a tetracycline antibiotic with anti-inflammatory effects—as an augmentation agent in the treatment of major depressive disorder (MDD).

This study was a pooled data analysis from two multisite, double-blinded, placebo-controlled trials of minocycline 200 mg/day taken over 12 weeks. Participants were healthy adults who had a diagnosis of non-treatment-resistant, moderate-to-severe MDD and had already been receiving treatment for depression for the prior 2–6 weeks. Treatments included antidepressants (86%–89%), antipsychotics (29%–30%), and benzodiazepines (36%–40%).

Patients (n = 112) who were randomized to adjunctive minocycline (n = 57) were twice as likely as those on placebo (n = 55) to show a response to treatment, defined as a reduction in the Hamilton Rating Scale for Depression (HAM-D) score > 50%. They were also twice as likely to experience remission, defined as a HAM-D score < 7. Specifically, 57% of the minocycline group showed a response to treatment and 32% achieved remission. In comparison, 23% of the placebo group responded to treatment and 11% experienced remission.

Rates of adverse effects were comparable in the minocycline and placebo groups. Interestingly, the best responders were participants who used pain medications, had a longer duration of illness, and were older.

Minocycline is affordable, readily available, and has a low likelihood of producing antibiotic resistance (Husain MI et al, J Psychopharmacol 2017;31(9):1166–1175). Be cautious when prescribing to women of reproductive age: Minocycline reduces the efficacy of hormonal contraceptives and should not be used during pregnancy (category D).

CHPR’S TAKE
Consider adding minocycline to your list of augmentation strategies for the treatment of major depression. It’s a safe and well-tolerated treatment that might be particularly effective for depressed patients with pain and longer duration of illness.
Hospital Psychiatry
KEYWORDS depression inflammation minocycline mood pharmacotherapy
Christina Guest, MD.

More from this author
www.thecarlatreport.com
Issue Date: September 13, 2021
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Agitation, CHPR, October-November-December 2021
Note From the Editor-in-Chief
IM Olanzapine Plus Benzodiazepines: Safe or Unsafe?
Can We Treat Depression by Targeting Inflammation?
Faster Refeeding of Patients With Anorexia Nervosa Appears Safe
Melatonin vs Memantine for ECT-Related Cognitive Impairment
Rapid-Onset Treatment for Pedophilic Disorder
Medications to Rapidly Treat Psychotic Agitation
Anticholinergic Drugs and Risk of Cognitive Impairment and Dementia
Treating Agitation in Patients with Dementia
DOWNLOAD NOW
Featured Book
  • CMFB2e_Cover.png

    (PRE-ORDER) Child Medication Fact Book for Psychiatric Practice, Second Edition (2023)

    All the important facts covering child and adolescent psychopharmacology.
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto104192710.jpg
    Hospital Psychiatry

    Management of Depression and Neurocognitive Impairment in Patients With HIV

    Strategies for the evaluation and management of HIV-associated mood and cognitive changes and potential drug interactions between psychiatric and antiretroviral medications. 

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.